<DOC>
	<DOCNO>NCT00884390</DOCNO>
	<brief_summary>The study investigate safety patient switch ReFacto AF ReFacto Factor VIII product .</brief_summary>
	<brief_title>Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings</brief_title>
	<detailed_description>The trial terminate prematurely 28 March 2013 , due inability recruit plan number subject . The decision terminate trial base safety efficacy concern agreement close study March 2013 agree EMA prior closure activity .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male patient great equal 12 year age severe hemophilia A ( FVIII : C le 1 % ) . Treatment history great 150 EDs prior recombinant plasmaderived FVIII replacement product . Transitioning ReFacto AF ReFacto recombinant plasmaderived FVIII replacement product . Serum albumin great equal low limit normal ( LLN ) . Platelet count great equal 100,000/µL . Prothrombin time ( PT ) less equal to1.25 × ULN , international normalize ratio ( INR ) less equal 1.5 . HIV positive subject must CD4 count great 200/µL HIV viral load le 200 particles/µL . Presence bleed disorder addition hemophilia A . A positive FVIII inhibitor , accord local laboratory , screen ; Bethesda Inhibitor Titer great 0.6 , regardless normal range test laboratory . Treated immunomodulatory therapy ( include Immune Tolerance Induction [ ITI ] ) screen period . Prior exposure moroctocog alfa ( AFCC ) . Known hypersensitivity hamster protein .</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Hemophilia A</keyword>
</DOC>